David Elder | Director
GlaxoSmithKline

David Elder, Director, GlaxoSmithKline

David P. Elder has thirty four years experience within the Pharmaceutical Industry. He is currently a director at GlaxoSmithKline Pharmaceuticals. He obtained a part-time PhD from Edinburgh University in1992 investigating the crystal structure and solid-state chemistry of a series of pharmaceutical salts. He is a member of the BP-Committee PCY: Pharmacy. He is a fellow of the Royal Society of Chemistry (FRSC), a Chartered Chemist, Chartered Scientist and is eligible to be a Qualified Person. He is a member of the EfPIA, PhRMA and PQRI sub-groups on genotoxic impurities. He is a committee member of Joint Pharmaceutical Analysis Group, a member of the Council of Analytical Division, RSC and an ex officio trustee of the Analytical Chemistry Trust Fund. He has authored 47 papers and has written 7 chapters in several Pharmaceutical textbooks. He has presented several webinars and 55 seminars at various UK, European and US scientific meetings.

Share this

Appearances at this years' conference:

Wednesday 23 May 2012- Accelerating early development stream


@ 11.15
Challenges in formulation development in first-in-human strategies

  • Attrition overview
  • Importance of solubility/permeability in absorption (BCS approach)
  • Predicting solubility/permeability/BCS
  • Predicting formulation strategy
  • Predicting degradation pathways
  • Excipient compatibility
  • Early formulation testing
  • Conclusions
     

  • › David Elder, Director, GlaxoSmithKline
Sponsors
Sponsors
Aptiv Solutions at Exploratory Clinical Development World Europe
Sponsors
CoreLab Partners at Exploratory Clinical Development World Europe
Sponsors
Optimed at Exploratory Clinical Development World Europe
Sponsors
Xceleron at Exploratory Clinical Development World Europe
Sponsors
iCardiac Technologies at Exploratory Clinical Development World Europe
Sponsors
PRA International at Exploratory Clinical Development World Europe